BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 52 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $198 | 0.0% | 200,000 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $198 | -3.9% | 200,000 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $206 | +3.5% | 200,000 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $199 | -99.9% | 200,000 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $199,000 | +0.5% | 200,000 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $198,000 | -99.5% | 200,000 | -50.0% | 0.00% | -99.3% |
Q1 2022 | $40,316,000 | +91.4% | 400,000 | +100.0% | 0.15% | +125.8% |
Q4 2021 | $21,062,000 | +20348.5% | 200,000 | +100.0% | 0.07% | – |
Q3 2021 | $103,000 | -50.5% | 100,000 | -50.0% | 0.00% | – |
Q2 2021 | $208,000 | -49.3% | 200,000 | -50.0% | 0.00% | -100.0% |
Q1 2021 | $410,000 | -4.7% | 400,000 | 0.0% | 0.00% | – |
Q4 2020 | $430,000 | +105.7% | 400,000 | +100.0% | 0.00% | -100.0% |
Q3 2020 | $209,000 | -57.5% | 200,000 | -50.0% | 0.00% | -50.0% |
Q2 2020 | $492,000 | +16.0% | 400,000 | 0.0% | 0.00% | -33.3% |
Q4 2019 | $424,000 | – | 400,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SHENKMAN CAPITAL MANAGEMENT INC | 19,413,000 | $19,245,611 | 1.50% |
SSI INVESTMENT MANAGEMENT LLC | 9,386,000 | $9,219,566 | 0.65% |
PFM Health Sciences, LP | 15,000,000 | $14,771,520 | 0.57% |
RWC Asset Management LLP | 11,000,000 | $10,848,475 | 0.52% |
Sonora Investment Management Group, LLC | 6,280,000 | $6,184,858 | 0.52% |
ADVENT CAPITAL MANAGEMENT /DE/ | 24,020,000 | $23,654,128 | 0.46% |
Lombard Odier Asset Management (Europe) Ltd | 7,224,000 | $7,124,489 | 0.34% |
MACKAY SHIELDS LLC | 10,123,000 | $9,943,520 | 0.28% |
PALISADE CAPITAL MANAGEMENT, LP | 9,478,000 | $9,323,983 | 0.25% |
Nicholas Investment Partners, LP | 2,940,000 | $2,887,868 | 0.20% |